Versões
- 2024-01-03 (2)
- 2023-12-29 (1)
Palavras-chave
hormônios
neurologia
psiquiatria
efeitos adversos anabolic steroids
hormones
neurology
psychiatry esteroides anabólicos
hormonas
neurología
psiquiatría
efectos adversos.
Como Citar
Resumo
O abuso de esteróides anabólicos androgênicos (EAAs) está associado a altas taxas de morbidade e mortalidade. A maior incidência desta negligência documentada em homens (taxa de prevalência de cerca de 6,4%), um terço dos quais desenvolvem reações adversas. Nesse sentido, o objetivo foi revisar os estudos publicados sobre as complicações neurológicas desencadeadas pelo uso indiscriminado de EAAs, com foco na patogênese das lesões no sistema nervoso (SN). Como resultado observou-se que no SN, esses estimulantes atuam por meio de sistemas de sinalização complexos que incluem a alteração neuroendócrina do eixo hipotálamo-hipófise-gonadal, modificação de neurotransmissores e seus receptores, bem como a indução de morte neuronal por apoptose em vários caminhos. Estas alterações neurológicas orgânicas podem levar a uma sintomatologia clínica com alterações neurológicas, do humor e do sono. Conseqüentemente, foram observados efeitos adversos variados de acordo com a classe de AAS utilizada, forma de administração e tempo de uso. Mesmo assim, até o momento, apenas algumas classes foram submetidas a análises científicas, quanto a dosagens, modo de administração e tempos específicos de exposição. Além disso, o uso e a produção ilegais dessas drogas não propiciam sua adequada aplicação, controle de qualidade e pureza. Concluiu-se que o abuso de AAS tem efeitos inimigas graves e complexos, incluindo graves problemas neurotóxicos.
Referências
Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin. Ther 2001; 23(9) 1355-1390.
Zelleroth S, Nylander E, Nyberg F, Grönbladh A, Hallberg M. Toxic impact of anabolic androgenic steroids in primary rat cortical cell cultures. Neuroscience. 2019; 397: 172- 183.
Evans NA. Current Concepts in Anabolic-Androgenic Steroids. The American Journal of Sports Medicine. 2004; 32 (2): 534-542.
NIDA – National Institute on Drug Abuse. Anabolic Steroids. Accessed on: 2018, November 27. Available at https://www.drugabuse.gov/publications/drugfacts/anabolic-steroids
Kanayama G, Kaufman MJ, Pope HG. Public health impact of androgens. Current Opinion in Endocrinology, Diabetes and Obesity. 2018; 25(3): 218-223.
Coward RM, Rajanahally S, Kovac JR, Smith RP, Pastuszak AW, Lipshultz LI. Anabolic steroid induced hypogonadism in young men. The Journal of urology. 2013; 190(6): 2200-5.
Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Annals of epidemiology. 2014; 24(5): 383-98.
Angell PJ, Green DJ, Lord R, Gaze D, Whyte G, George KP. Acute cardiovascular responses to resistance exercise in anabolic steroids users: A preliminary investigation. Science and Sports. 2018; 33(6): 339-346.
Horwitz H, Andersen JT, Dalhoff KP. Health consequences of androgenic anabolic steroids. J Intern Med 2018; doi: 10.1111/joim.12850. [Epub ahead of print]
De Ronde, W. Preventing anabolic steroid abuse; a long way to go. Journal of Internal Medicine. 2018. doi:10.1111/joim.12858
M?dra? M, Brona A, Jó?ków P. The central effects of androgenic-anabolic steroid use. Journal of Addiction Medicine. 2018; 12(3): 184-192.
Mazzeo F. (2018). Anabolic steroid use in sports and in physical activity: Overview and analysis. Sport Mont. 2018; 16(3): 113-118.
Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov. 2006; 5: 160-170
Orlando R, Caruso A, Molinaro G. Nanomolar concentrations of anabolic- androgenic steroids amplify excitotoxic neuronal death in mixed mouse cortical cultures. Brain Res. 2007; 1165: 21-29.
Caraci F, Pistara V, Corsaro A. Neurotoxic properties of the anabolic androgenic steroids nandrolone and methandrostenolone in primary neu- ronal cultures. J Neurosci Res. 2011; 89: 592-600.
Pope HGJR, Kanayama G, Hudson JI. Risk factors for illicit anabolic-an- drogenic steroid use in male weightlifters: a cross-sectional cohort study. Biol Psychiatry. 2012; 71: 254- 261
Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HGJR. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009; 104: 1966-1978.
Christou MA, Christou PA, Markozannes G, Tsatsoulis A, Mastorakos G, Tigas S. Effects of Anabolic Androgenic Steroids on the Reproductive System of Athletes and Recreational Users: A Systematic Review and Meta-Analysis. Sports Med 2017; 47(9):1869- 1883.
Fortunato RS, Rosenthal D, Carvalho DP. Abuso de Esteróides Anabolizantes e seu Impacto sobre a Func?a?o Tireóidea. Arq Bras Endocrinol Metab. 2007; 51(9): 1417-1424.
Bahrke MS, Yersalis CE, Kopstein AN, Stephens JA. Risk factors associated with anabolic-androgenic steroid use among adolescents. Sports Med. 2000; 29 (6): 397-405.
Silva PRP, Danielski R, Czepielewski MA. Esteroides anabolizantes no esporte. RBME. 2002; 8: 235-243
Ma F, Liu D. 17b-trenbolone, an anabolic-androgenic steroid as well as an environmental hormone, contributes to neurodegeneration. Toxicology and applied pharmacology. 2015; 282(1): 68-76.
Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS. Psychiatric side effects induced by supraphysiological doses of combina- tions of anabolic steroids correlate to the severity of abuse. Eur Psychiatry. 2006; 21: 551-562
Talih F, Fattal O, Malone D Jr. Anabolic steroid abuse: psychiatric and phy- sical costs. Cleve Clin J Med. 2007; 74: 341-344.
Tucci P, Morgese M, Colaianna M, Zotti M, Schiavone S, Cuomo V. Neurochemical consequence of steroid abuse: stanozolol-induced monoaminergic changes. Steroids. 2012; 77: 269-275.
Pomara C, Neri M, Bello S, Fiore C, Riezzo I, Turillazzi E. Neurotoxicity by synthetic androgen steroids: oxidative stress, apoptosis, and neuropathology: a review. Curr Neuropharmacol. 2015; 13 (1):132-145.
Amiaz R, Seidman SN. Testosterone and depression in men. Curr Opin Endocrinol Diabetes Obes. 2008; 15 (3): 278-283
Zarrouf FA, Artz S, Griffith J, Sirbu C, Kommor M. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract. 2009; 15 (4): 289- 305.
Schwartzer JJ, Ricci LA, Melloni R. Interactions be- tween the dopaminergic and GABAergic neural systems in the lateral anterior hypothalamus of aggressive AAS- treated hamsters. Behav Brain Res. 2009; 203 (1): 15-22
Masonis AE, Mccarthy MP. Effects of the androgenic/ anabolic steroid stanozolol on GABAA receptor function: GABA-stimulated 36Cl- influx and [35S] TBPS binding. J Pharmacol Exp Ther. 1996; 279 (1):186-193
Hughes TK, Rady PL, Smith EM. Potential for the effects of anabolic steroid abuse in the immune and neuroendocrine axis. J Neuroimmunol. 1998; 83 (1-2): 162- 167.
Kindlundh A, Lindblom J, Bergstrom L, Nyberg F. The anabolic-androgenic steroid nandrolone induces alterations in the density of serotonergic 5HT1B and 5HT2 receptors in the male rat brain. Neuroscience. 2003; 119 (1):113-120.
Costine BA, Oberlander JG, Davis MC, Penatti CA, Porter DM, Leaton RN, Henderson LP. Chronic anabolic androgenic steroid exposure alters corticotropin releasing factor expression and anxiety-like behaviors in the female mouse. Psychoneuroendocrinology. 2010; 35 (10): 1473-1485.
Kash Tl, Winder DG. Neuropeptide Y and corticotropin- releasing factor bi- directionally modulate inhibitory synaptic trans- mission in the bed nucleus of the stria terminalis. Neuropharmacology. 2006; 51(5): 1013-1022.
Tasan RO, Bukovac A, Peterschmitt Yn, Sartori Sb, Landgraf R, Singewald N, Sperk G. Altered GABA transmission in a mouse model of increased trait anxiety. Neuroscience. 2011; 183: 71-80.
Pope HG, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry. 1994; 51 (5): 375- 382.
Pinna G, Agis-Balboa Rc, Pibiri F, Nelson M, Guidotti A, Costa E. Neurosteroid biosynthesis regulates sexually dimorphic fear and aggressive behavior in mice. Neurochem Res. 2008; 33 (10): 1990-2007
Ostlund H, Keller E, Hurd YL. Estrogen receptor gene ex- pression in relation to neuropsychiatric disorders. Ann N Y Acad Sci. 2003; 1007: 54-63.
Kanayama G, Hudson JI, Popope J. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern? Drug Alcohol Depend. 2008; 98: 1-12.
Amsterdam JV, Opperhuizen A, Hartgens F. Adverse health effects of anabolicandrogenic steroids. Regulatory Toxicology and Pharmacology. 2010; 57: 117- 123.
Birgner C, Kindlundh-Hogberg Am, Oreland L, et al. Reduced activity of monoamine oxidase in the rat brain following repeated nandrolone dec- anoate administration. Brain Res. 2008; 1219: 103-110.
Ip EJ, Trinh K, Tenerowicz MJ, Pal J, Lindfelt TA, Perry PJ. Characteristics and behaviors of older male anabolic steroid users. J Pharm Pract. 2015; 28 (5): 450- 456.
Sato SM, Schulz KM, Sisk CL, Wood RI. Adolescents and androgens, receptors and rewards. Horm Behav. 2008; 53 (5): 647-658.
Malone DA, Dimeff RJ, Lombardo JA, Sample RH. Psychiatric effects and psychoactive substance use in anabolic- androgenic steroid users. Clin J Sport Med. 1995; 5 (1): 25-31.
Piacentino D, Kotzalidis GD, Del Casale A, Aromatario MR, Pomara C, Girardi P, Sani G. Anabolic-androgenic steroid use and psychopathology in athletes. A systematic review. Curr Neuropharmacol. 2015; 13 (1): 101-121.
Penatti CA, Costine BA, Porter D. Effects of chronic exposure to an anabolic androgenic steroid cocktail on alpha5-receptor-mediated GABAergic transmission and neural signaling in the forebrain of female mice. Neuroscience. 2009; 161: 526-537.
Oberlander JG, Porter DM, Penatti CA, Henderson LP. Anabolic androgenic steroid abuse: multiple mechanisms of regu- lation of GABAergic synapses in neuroendocrine control regions of the rodent forebrain. J Neuroendocrinol. 2012; 24 (1): 202-214.
Clark AS, Henderson LP. Behavioral and physiological responses to anabolic- androgenic steroids. Neurosci Biobehav Rev. 2003; 27: 413-436
Zitzmann M. Testosterone and the brain. Aging Male. 2006; 9: 195-199
Matrisciano F, Modafferi AM, Togna GI. Repeated anabolic androgenic steroid treatment causes antidepressant-reversible alterations of the hypo- thalamic- pituitary-adrenal axis, BDNF levels and behavior. Neuropharmacology 2010; 58: 1078- 1084
Leibenluft E, Schmidt Pj, Turner Eh, Danaceau Ma, Ashman Sb, Wehr Ta, et al. Effects of leuprolide-induced hypogonadism and testosterone repla- cement on sleep, melatonin, and prolactin secretion in men. J Clin Endocrinol Metab. 1997; 82: 3203-3207
Venancio DP, Tufik S, Garbuio SA. Effects of anabolic androgenic steroids on sleep patterns of individuals practicing resistance exercise. Eur J Appl Physiol. 2008; 102(5):555-60.
Liu PY, Yee B, Wishart SM, Jimenez M, Jung DG, Grunstein RR. The short-term eVects of high-dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab. 2003; 88: 3605-3613.
Trenton AJ, Currier GW. Behavioural manifestations of anabolic steroid use. CNS Drugs. 2005; 19: 571-595.
Bjornebekk A, Walhovd KB, Jorstad ML. Structural brain imaging of long- term anabolic-androgenic steroid users and nonusing weightlifters. Biol Psychiatry. 2017; 82: 294-302
Silva DK, Esteves A, Rossi WC, Nogueira DA. Quantidade de Ce?lulas de Purkinje no Cerebelo de Camundongos Sob o Uso de Esteróides Anabolizantes. Rev Neurocienc. 2012; 20 (2): 200-203.
Bueno A, Carvalho FB, Gutierres JM, Lhamas C, Andrade CM. A comparative study of the effect of the dose and exposure duration of anabolic androgenic steroids on behavior, cholinergic regulation, and oxidative stress in rats. PLoS One. 2017; 12 (6): e0177623
Kaufman MJ, Janes AC, Hudson JI. Brain and cognition abnormalities in long-term anabolic-androgenic steroid users. Drug Alcohol Depend. 2015; 152: 47 -56.
Ribeiro CM, Silva DC, Damia?o B, Alves DM, Freitas AC, Ju?nior VCR, Esteves A. Ana?lise quantitativa de ce?lulas de Purkinje em camundongos sob o uso dos esteroides anabolizantes. Rev. Neurocienc. 2014; 22(3): 432-437.
Estrada M, Varshney A, Ehrlich BE. Elevated testosterone induces apoptosis in neuronal cells. J Biol Chem. 2006; 281: 25492-25501.